Tivantinib|905854-02-6|(ARQ 197; (3R,4R)-ARQ 198)-陌孚医药/Medlife

您当前的位置：

Tivantinib (Synonyms: ARQ 197; (3R,4R)-ARQ 198)

目录号: PL05082 纯度: ≥99%

CAS No. :905854-02-6

商品编号	规格	价格	会员价
PL05082-5mg	5mg	¥896.00	请登录
PL05082-10mg	10mg	¥1345.00	请登录
PL05082-50mg	50mg	¥4500.00	请登录
PL05082-100mg	100mg	¥6107.00	请登录
PL05082-200mg	200mg	¥10929.00	请登录
PL05082-500mg	500mg	¥21698.00	请登录
PL05082-1g	1g	询价	询价
PL05082-5g	5g	询价	询价
PL05082-10mM*1mLinDMSO	10mM*1mLinDMSO	¥986.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Tivantinib
中文别名	(3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-ij]喹啉)-4-(1H-吲哚)-2,5-吡咯烷二酮;(3R,4R)-3-(5,6-二氢-4H-吡咯并[3,2,1-IJ]喹啉-1-基)-4-(1H-吲哚-3-基)吡咯烷-2,5-二酮;3,11-二氯-6,11-二氢-6-甲基-二苯并[c,f][1,2]硫氮杂卓 5,5-二氧化物;祖师麻甲素.瑞香素
英文名称	Tivantinib
英文别名	(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione;Tivantinib;ARQ 197;Tivantinib (ARQ 197);2,5-Pyrrolidinedione, 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij] quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R,4R)-;2,5-Pyrrolidinedione,3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-, (3R...;3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione;ARQ 197 (ARQ-197,Tivantinib);ARQ 197 (Tivantinib);ARQ-197;(-)-3(R),4(R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione;(-)-3(R),4(R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione,(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione;(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolid;TIVANTINIB ARQ-197;ARQ197;PJ4H73IL17;(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione;Tivantinib [USAN:INN];Tivantinib; ARQ197;ARQ 197, Tivantinib;Tivantinib (JAN/USAN/INN);GTPL7948;(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione (ACI)
Cas No.	905854-02-6
分子式	C₂₃H₁₉N₃O₂
分子量	369.42
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Tivantinib 是一种高选择性 c-Met 酪氨酸激酶抑制剂，K_i 为 355 nM。

生物活性

Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a K i of 355 nM.

性状

Solid

IC50 & Target[1][2]

Ki: 355 nM (c-Met)

体外研究(In Vitro)

Tivantinib (ARQ 197) selectively inhibits c-Met activity in cell-free and cell-based assays. c-Met-expressing cancer cell lines treated with Tivantinib display either a dose-dependent loss of proliferative capacity or caspase-dependent apoptosis that positively correlates with either ligand-dependent c-Met activity or constitutively active c-Met. To examine the biochemical mode of inhibition of Tivantinib, kinetic analyses are done using recombinant human c-Met in a filtermat-based assay. The Km of ATP is 50.5±2.2 μM, which is similar to the Km value of ATP. In these kinetic studies, Tivantinib inhibits human recombinant c-Met with a calculated inhibitory constant (Ki) of ~355 nM. In vitro exposure to Tivantinib inhibits constitutive c-Met phosphorylation in HT29 and MKN-45 cells, and HGF-induced c-Met phosphorylation in MDA-MB-231 and NCI-H441

体内研究(In Vivo)

Pharmacodynamically, the phosphorylation of c-Met in human colon xenograft tumors (HT29) is strongly inhibited by Tivantinib (ARQ 197), as assessed by a dramatic reduction of c-Met autophosphorylation 24 hours after a single oral dose of 200 mg/kg of Tivantinib. This same dosage in mice shows that tumor xenografts are exposed to sustained plasma levels of Tivantinib, consistent with the observed pharmacodynamic inhibition of c-Met phosphorylation and inhibition of proliferation of c-Met harboring cancer cell lines. A C max of 5.73 μg/mL (13 μM), an area under the concentration-time curve of 12.1 μg/mL h, and a t 1/2 of 2.4 hours are measured. Plasma levels of Tivantinib 10 hours after dosing are determined to be 1.3 μM, >3-fold above the biochemical inhibitory constant of Tivantinib for c-Met. has

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Munshi N, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010 Jun;9(6):1544-53.
[2]. Bai YL, et al. Quantitative analysis of tivantinib in rat plasma using ultra performance liquid chromatography with tandem mass spectrometry. J Pharm Biomed Anal. 2016 Jul 15;126:98-102.

溶解度数据	In Vitro: DMSO : 100 mg/mL (270.69 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation